Best Meds for Longevity: A Realistic Guide to What the Evidence Actually Supports

The drug longevity physicians talk about most. Originally for type 2 diabetes, it has been used safely for over 60 years. The longevity interest began with a striking finding: diabetics on metformin appeared to outlive non-diabetic controls. It activates AMPK, lowers chronic inflammation, improves insulin sensitivity, and may reduce some age-related cancers. The TAME trial is the first FDA-approved study designed to test whether a drug can slow aging itself, and metformin is the drug.

The compound that gets researchers most animated. An mTOR inhibitor first used to prevent transplant rejection, it has extended lifespan more consistently and across more species than anything else tested, including in mice started late in life. By dialing down mTOR, the master regulator of cell growth, it promotes autophagy, shifting cells from build mode to repair mode. At low weekly doses, early human data suggests it may enhance immune function rather than suppress it: one study improved elderly patients’ response to the flu vaccine.

Semaglutide and tirzepatide dominate the headlines as weight-loss shots, but the longevity case runs deeper. The SELECT trial showed semaglutide cut major cardiovascular events by 20% in overweight and obese adults, regardless of diabetes status, with later data hinting at kidney, heart failure, and even cancer and neurodegeneration benefits. Since visceral fat is one of the strongest drivers of accelerated aging, these injectables address it more effectively than any prior drug, with benefits that exceed what weight loss alone would predict. This is the answer for anyone searching for the best longevity shots for metabolic health.

Testosterone declines roughly 1 to 2% per year in men from about age 30. By the 50s and 60s, levels can fall below what is needed for muscle, bone density, cognition, and metabolic health. Adequate testosterone supports several pillars of healthspan, especially lean muscle, the single strongest predictor of functional independence in aging. The TRAVERSE trial, the largest RCT of TRT in older men, found no increased risk of major cardiovascular events, and physiologic replacement has not been shown to raise prostate cancer risk in men without pre-existing disease. The key word is physiologic: the goal is optimization, not maximization. Another injectable that earns its place in a metabolic-health protocol.

Statins are not exciting, but the evidence base for cardiovascular risk reduction is arguably the strongest of anything on this list. Cardiovascular disease is the number one killer globally, and ApoB-containing lipoproteins drive plaque over decades. Statins cut LDL effectively and, across dozens of large trials, significantly reduce heart attacks, strokes, and cardiovascular death. The case for starting early is cumulative: the longer your arteries are exposed to elevated ApoB, the greater your lifetime risk, so acting before an event dramatically changes the math.

Acarbose rarely makes headlines but has a quietly compelling profile. It slows carbohydrate digestion, blunting the post-meal glucose spikes that drive insulin resistance over time. In the Interventions Testing Program, one of the most rigorous animal lifespan studies ever run, acarbose significantly extended lifespan in male mice, and human data shows it reduces glucose variability and may lower cardiovascular events in people with impaired glucose tolerance.

NAD+ is a coenzyme essential to cellular energy, DNA repair, and sirtuin activation, and its levels fall significantly with age. NMN and NR are precursors the body converts to NAD+. Animal studies show improvements in metabolic function, endurance, and aging markers, and David Sinclair has been a vocal proponent. The honest assessment: human data is limited. Some trials raise blood NAD+, but whether that translates to reduced disease or longer life is unproven, and as supplements they carry less oversight and variable quality.